Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
$0.73
-18.1%
$0.75
$0.42
$1.89
$8.01M0.39196,500 shs423,449 shs
Newfield Exploration stock logo
NFX
Newfield Exploration
$17.07
$0.00
$12.45
$31.46
$3.43B1.858.80 million shsN/A
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
C$0.02
-25.0%
C$0.02
C$0.02
C$0.10
C$984K1.5152,289 shs4,000 shs
Valaris Limited stock logo
VAL
Valaris
$73.60
+2.4%
$69.96
$55.53
$78.92
$5.33B1.2902,554 shs1.30 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
+4.21%+26.96%+11.09%+48.36%-42.29%
Newfield Exploration stock logo
NFX
Newfield Exploration
0.00%0.00%0.00%0.00%0.00%
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
0.00%0.00%0.00%0.00%0.00%
Valaris Limited stock logo
VAL
Valaris
+1.55%+10.51%-2.46%+15.52%+22.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
3.053 of 5 stars
3.55.00.00.02.51.70.6
Newfield Exploration stock logo
NFX
Newfield Exploration
N/AN/AN/AN/AN/AN/AN/AN/A
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
3.1255 of 5 stars
3.51.00.00.01.81.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$6.50796.55% Upside
Newfield Exploration stock logo
NFX
Newfield Exploration
N/AN/AN/AN/A
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
N/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
3.00
Buy$100.0035.87% Upside

Current Analyst Ratings

Latest VAL, NFX, PAS, CMMB, and RLM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2024
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$6.00
5/2/2024
Valaris Limited stock logo
VAL
Valaris
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
3/5/2024
Valaris Limited stock logo
VAL
Valaris
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
2/23/2024
Valaris Limited stock logo
VAL
Valaris
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$107.00 ➝ $105.00
2/14/2024
Valaris Limited stock logo
VAL
Valaris
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$106.00 ➝ $105.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$1.54 per shareN/A
Newfield Exploration stock logo
NFX
Newfield Exploration
$1.77B1.94$4.50 per share3.79$7.05 per share2.42
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
N/AN/AC$0.00 per share55.00C($0.02) per shareN/A
Valaris Limited stock logo
VAL
Valaris
$1.78B2.99$2.72 per share27.02$27.40 per share2.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$24.22M-$2.12N/AN/AN/AN/A-114.00%-88.53%5/9/2024 (Confirmed)
Newfield Exploration stock logo
NFX
Newfield Exploration
$427M$2.157.945.170.3721.14%43.65%13.21%N/A
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
N/A-C$0.01N/AN/AN/AN/A-340.40%N/A
Valaris Limited stock logo
VAL
Valaris
$865.40M$11.436.447.09N/A44.93%3.81%1.62%8/6/2024 (Estimated)

Latest VAL, NFX, PAS, CMMB, and RLM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$0.20N/A+$0.20N/AN/AN/A
5/1/2024Q1 2024
Valaris Limited stock logo
VAL
Valaris
$0.40$0.35-$0.05$0.35$503.00 million$525.00 million      
3/7/202412/31/2023
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$0.40-$0.26+$0.14-$0.26N/AN/A  
2/21/2024Q4 2023
Valaris Limited stock logo
VAL
Valaris
$0.29$0.61+$0.32-$10.08$484.00 million$483.80 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Newfield Exploration stock logo
NFX
Newfield Exploration
N/AN/AN/AN/AN/A
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
N/AN/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/A
4.32
4.32
Newfield Exploration stock logo
NFX
Newfield Exploration
1.30
0.72
0.70
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
882.79
0.03
0.17
Valaris Limited stock logo
VAL
Valaris
0.53
1.57
1.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
46.05%
Newfield Exploration stock logo
NFX
Newfield Exploration
97.87%
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
N/A
Valaris Limited stock logo
VAL
Valaris
96.74%

Insider Ownership

CompanyInsider Ownership
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
11.91%
Newfield Exploration stock logo
NFX
Newfield Exploration
0.59%
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
15.43%
Valaris Limited stock logo
VAL
Valaris
0.12%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
2011.05 million9.73 millionNot Optionable
Newfield Exploration stock logo
NFX
Newfield Exploration
N/A200.93 millionN/AOptionable
Pascal Biosciences Inc. stock logo
PAS
Pascal Biosciences
665.59 millionN/ANot Optionable
Valaris Limited stock logo
VAL
Valaris
5,98572.41 million72.32 millionOptionable

VAL, NFX, PAS, CMMB, and RLM Headlines

SourceHeadline
Valaris Jack-up Using AI for Man Overboard DetectionValaris Jack-up Using AI for Man Overboard Detection
marinelink.com - May 7 at 7:25 PM
Benchmark Co. Reaffirms Their Buy Rating on Valaris (VAL)Benchmark Co. Reaffirms Their Buy Rating on Valaris (VAL)
markets.businessinsider.com - May 7 at 3:06 AM
What Analysts Are Saying About Valaris StockWhat Analysts Are Saying About Valaris Stock
benzinga.com - May 6 at 5:05 PM
Valaris’ 1Q Sets Positive Tone for OffshoreValaris’ 1Q Sets Positive Tone for Offshore
finance.yahoo.com - May 6 at 5:05 PM
Q2 2024 Earnings Forecast for Valaris Limited (NYSE:VAL) Issued By Capital One FinancialQ2 2024 Earnings Forecast for Valaris Limited (NYSE:VAL) Issued By Capital One Financial
americanbankingnews.com - May 6 at 1:22 AM
Benchmark Reaffirms Buy Rating for Valaris (NYSE:VAL)Benchmark Reaffirms Buy Rating for Valaris (NYSE:VAL)
americanbankingnews.com - May 5 at 5:02 AM
Valaris Limited (NYSE:VAL) Q1 2024 Earnings Call TranscriptValaris Limited (NYSE:VAL) Q1 2024 Earnings Call Transcript
msn.com - May 3 at 6:09 PM
Equinor starts drilling well on billion-barrel Argentina prospectEquinor starts drilling well on billion-barrel Argentina prospect
upstreamonline.com - May 3 at 12:44 PM
Valaris Ltd (VAL) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Income DipsValaris Ltd (VAL) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Income Dips
finance.yahoo.com - May 2 at 4:34 PM
Valaris Limited 2024 Q1 - Results - Earnings Call PresentationValaris Limited 2024 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 2 at 1:03 PM
Valaris (NYSE:VAL) Stock Rating Reaffirmed by BenchmarkValaris (NYSE:VAL) Stock Rating Reaffirmed by Benchmark
marketbeat.com - May 2 at 12:35 PM
Should You Add Valaris Limited (VAL) to Your Portfolio?Should You Add Valaris Limited (VAL) to Your Portfolio?
msn.com - May 2 at 9:27 AM
Retirement Systems of Alabama Purchases 43,368 Shares of Valaris Limited (NYSE:VAL)Retirement Systems of Alabama Purchases 43,368 Shares of Valaris Limited (NYSE:VAL)
marketbeat.com - May 2 at 6:15 AM
Valaris Reports First Quarter 2024 ResultsValaris Reports First Quarter 2024 Results
businesswire.com - May 1 at 6:27 PM
Valaris brings in $480m worth of new rig dealsValaris brings in $480m worth of new rig deals
splash247.com - May 1 at 1:18 PM
Valaris adds $480 million to its backlog thanks to hefty BP dealValaris adds $480 million to its backlog thanks to hefty BP deal
upstreamonline.com - May 1 at 1:18 PM
Valaris Issues Fleet Status ReportValaris Issues Fleet Status Report
businesswire.com - April 30 at 9:52 PM
Van ECK Associates Corp Reduces Position in Valaris Limited (NYSE:VAL)Van ECK Associates Corp Reduces Position in Valaris Limited (NYSE:VAL)
marketbeat.com - April 30 at 11:47 AM
UK offshore explorer hits out at political meddling hurting its growth plansUK offshore explorer hits out at political meddling hurting its growth plans
upstreamonline.com - April 30 at 3:20 AM
Esgian Week 17 Report: New Contracts for the North SeaEsgian Week 17 Report: New Contracts for the North Sea
marinelink.com - April 28 at 10:48 PM
Equinor rolls up its sleeves for imminent Argentina exploration wellEquinor rolls up its sleeves for imminent Argentina exploration well
upstreamonline.com - April 25 at 9:14 AM
Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL)Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL)
marketbeat.com - April 23 at 4:51 AM
John Fredriksen ally wins seat on board of potential takeover target International SeawaysJohn Fredriksen ally wins seat on board of potential takeover target International Seaways
tradewindsnews.com - April 18 at 10:48 PM
Valaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLCValaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLC
marketbeat.com - April 18 at 9:34 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Chemomab Therapeutics logo

Chemomab Therapeutics

NASDAQ:CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Newfield Exploration logo

Newfield Exploration

NYSE:NFX
Newfield Exploration Company, an independent energy company, engages in the exploration, development, and production of crude oil, natural gas, and natural gas liquids in the United States. The company has operations principally in the Anadarko and Arkoma basins of Oklahoma, the Williston Basin of North Dakota, and the Uinta Basin of Utah. It also holds oil producing assets offshore China. The company was founded in 1988 and is headquartered in The Woodlands, Texas.
Pascal Biosciences logo

Pascal Biosciences

CVE:PAS
Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.
Valaris logo

Valaris

NYSE:VAL
Valaris Limited, together with its subsidiaries, provides offshore contract drilling services Gulf of Mexico, South America, North Sea, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Floaters, Jackups, ARO, and Other. It owns an offshore drilling rig fleet, which include drillships, dynamically positioned semisubmersible rigs, moored semisubmersible rig, and jackup rigs. It serves international, government-owned, and independent oil and gas. Valaris Limited was founded in 1975 and is based in Hamilton, Bermuda.